British Journal of Cancer

OCT 6, 2026 · JOURNAL ARTICLE

Integrated spatial and single-cell transcriptomics uncover IFI6⁺ regulatory T-cells and SPP1⁺ macrophages immunosuppressive niches in colorectal cancer

British Journal of Cancer

Abstract Background In colorectal cancer (CRC), tumor-immune interactions are critical drivers of tumorigenesis, immune evasion, and therapeutic response. Therefore, a deeper spati

SEP 26, 2026 · JOURNAL ARTICLE

Small extracellular vesicles from the plasma of head and neck cancer patients induce dysfunctional T cell phenotypes

British Journal of Cancer

Abstract Background Head and neck cancer (HNC) is highly immunosuppressive. Despite advances with immune checkpoint (IC) inhibitors, many HNC patients fail to respond. Tumour-deriv

SEP 26, 2026 · JOURNAL ARTICLE

A plasma derived hypoxia signature predicts benefit from hypoxia-modifying radiotherapy and reveals dynamic humoral immune modulation in bladder cancer

British Journal of Cancer

Abstract Introduction Hypoxia is a hallmark of solid tumours and drives radioresistance, yet no hypoxia biomarkers are used clinically. We explored nanoproteomics to identify a pla

SEP 16, 2026 · JOURNAL ARTICLE

Menopausal hormone therapy and primary liver cancer: long-term follow-up of the women’s health initiative randomized trials

British Journal of Cancer

Abstract Background: Long-term results on liver cancer incidence and mortality are reported from two Women’s Health Initiative randomized trials evaluating menopausal hormone thera

AUG 8, 2026 · JOURNAL ARTICLE

Exploring PDLIM2 as a prognostic biomarker and therapeutic target in lung adenocarcinoma

British Journal of Cancer

A real finding from a sound but limited study: PDLIM2 shows prognostic value in a large retrospective cohort and preclinical efficacy in mouse models, but lacks clinical trial data and the therapeutic benefit remains unvalidated in humans.